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1. Introduction 
Recently, it was reported that the tuberculosis mortality in 2009 has dropped to 35% since 
1990 (WHO, 2010). Nevertheless, the disease caused by the facultative intracellular bacterial 
pathogen Mycobacterium tuberculosis still remains the leading cause of death from a single 
bacterial species (Coker, 2004; Russell et al., 2010). The emergence of Multi-Drug Resistant 
(MDR) and Extreme Drug Resistant (XDR) strains of M. tuberculosis leads to prolonged 
treatment which drastically increases the therapy costs. 
M. tuberculosis shows a remarkable property of existing in different states of invasion 
(infection), colonization and persistence (Casadevall & Pirofski, 2000). It also has 
outstanding mechanisms to escape from elimination and has a high degree of intrinsic 
resistance to most antibiotics, chemotherapeutic agents and immune eradication (Brennan & 
Nikaido, 1995; Coker, 2004). The major obstacle for host defence mechanisms and 
therapeutic intervention is the unusual robust cell wall which is unique among prokaryotes, 
and is a major determinant of virulence of the bacterium. The cell wall is critical for long-
term persistence of M. tuberculosis in the hostile environment of the host's cells and for 
progression of tuberculosis (Barry et al., 1998). Approximately one-half of the cell wall mass 
is comprised of mycolic acids (Brennan & Nikaido, 1995). In the cell envelope, mycolic acids 
are esterified to the terminal pentaarabinofuranosyl unit of arabinogalactan, which is a 
peptidoglycan-linked polysaccharide. The outer envelope consists of trehalose 6,6'-
dimycolate (TDM; cord factor) and TMM (trehalose 6,6'-monomycolate, the biosynthetic 
precursor of TDM), where the mycolic acids of TDM interact with the mycolyl-residues from 
the layer beneath (Brennan & Nikaido, 1995). The mycolic acid-containing layers have width 
of ~10 nm and limit the penetration of hydrophilic substances, whereas the inner saccharide 
layer inhibits the penetration of lipophilic substances. The high abundance of mycolic acids 
in the outer cell envelope is the main barrier for water soluble antibiotics (Brennan, 2003; 
Coker, 2004). 
The purpose of this review is to highlight the importance of the cord factor as one of the 
most unique determinant for Mycobacterium tuberculosis virulence. This article will especially 
focus on the steps of the cord factor biosynthesis, i.e., the transfer of mycolic acid from a 
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TMM to another TMM to form TDM by Ag85 complex enzymes. The Ag85 complex is one 
of the promising targets for novel antimycobacterial drugs and vaccines. We present our 
recently developed high throughput screening (HTS) assays suitable for the identification of 
potential inhibitors against Ag85.   
2. Discovery of the cord factor (Trehalose 6,6´-di-mycolate; TDM) 
In 1884, Robert Koch described M. tuberculosis bacilli grown in culture as rope-like structures 
(Koch, 1884). More than half a century later, in 1947 Middlebrook found that the ability to 
form cords under specific conditions is an “essential accompaniment of virulence” 
(Middlebrook et al., 1947). In 1950 Bloch extracted the substance responsible for cord 
formation from virulent organisms and identified it as a “toxic substance” (Bloch, 1950). 
The removal of the substance with petroleum ether resulted in somehow avirulent 
organisms but did not affect the growth of the bacilli. This suggested that the substance was 
located at the surface and since it was obtained only from “cordforming” organisms it was 
called “cord factor” (Bloch, 1950; Middlebrook et al., 1947). Six years later the cord factor 
was finally identified as trehalose 6,6´-di-mycolate (TDM) by Noll (Behling et al., 1993a; 
Noll, 1956). TDM is the most abundant glycolipid produced by virulent M. tuberculosis 
(Hunter et al., 2006a). TDM molecules consist of trehalose (TDM glycan-head). Trehalose is 
abundant in mycobacteria as a free component (Elbein & Mitchell, 1973; Elbein et al., 2003). 
In the cord factor trehalose is esterified to two mycolic acid residues and the residues length 
is variable from species to species (Fig. 1). Mycobacterial mycolic acids contain generally 20–
80 carbons (Spargo et al., 1991).  
 
Fig. 1. Structure of trehalose 6,6´-di-mycolate (TDM, cord factor). 
The cord factor is comprised of trehalose which esterifed to two mycolic acid residues 
through their 6- and 6'-hydroxyl groups. 
2.1 Effects of the cord factor on the immune system 
TDM inhibits the process of phagosome-lysosome fusion and is thus a key compound for 
the survival of the bacillus inside the host´s phagosomes (Indrigo et al., 2002). TDM induces 
a broad range of cytokine secretion in the host´s immune system, especially production of 
IL-1ǃ, IL-6, and TNF in macrophages (Matsunaga & Moody, 2009). In the recent years it has 
been shown that TDM is a key driver of secondary and cavitary disease type of tuberculosis 
(Hunter et al., 2006b). Despite the various severe effects on the host immune system the host 
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receptor could not been identified. In 2009 Ishikawa et al. could demonstrate that 
macrophage inducible C-type lectin (Mincle) is an essential receptor for TDM (Ishikawa et 
al., 2009).  
2.2 TDM as vaccine adjuvant  
In the last years TDM has been used intensively as immunomodulatory and vaccine 
adjuvant (Behling et al., 1993b; Noll, 1956). TDM can reproduce several pathophysiologic 
properties of M. tuberculosis infection including granuloma formation and induction of 
proinflammatory cytokines, such as  IL-1ǃ, IL-6, and TNF in macrophages (Matsunaga & 
Moody, 2009). TNF (cachexin) has several toxic effects on host physiology, including sepsis, 
fever syndromes and cachexia (Silva & Faccioli, 1988).  
Doses as little as 1–5 µg are granulomagenic in the lungs of mice (Bekierkunst et al., 1969). 
Moreover TDM increases the production of antibodies (Behling et al., 1993b; Perez et al., 
1994; Perez et al., 2000) and it up-regulates the expression of MHCII on macrophages (Ryll et 
al., 2001). TDM also induces in vivo production of IL-12 (Oswald et al., 1997). Injected as 
mineral oil solution (Silva & Faccioli, 1988) TDM forms monolayers, where the mycolic acids 
are exposed. In the monolayer form TDM is highly toxic (lethal dose in mice: LD50 ~30 μg) 
and kills macrophages in minutes (Hunter et al., 2006b). In aqueous suspension TDM forms 
micelles, where the mycolic acid groups are completely covered and TDM is non-toxic 
(lethal dose in mice: LD50 >50,000 μg). Micellar TDM prevents phagosome/lysosome fusion 
and thus promotes the survival of mycobacteria in the macrophage. Nevertheless, until now 
there is no experimental evidence for the existence or formation of TDM micelles or 
monolayers in vivo.  Due to its strong immunstimulatory effect, several studies have used 
TDM as a potential adjuvant in different vaccination models. In 1976 Saito et al. were the 
first who described the cord factor as good adjuvant in mice and rats but with only low 
adjuvant effect in guinea pigs (Saito et al., 1976). Lima et al. could show that microspheres, 
containing TDM with a Hsp65-encoding DNA plasmid, were able to protect vaccinated mice 
against virulent M. tuberculosis (Lima et al., 2003) and against Leishmania major infection 
(Coelho et al., 2006). The major problem using TDM as adjuvant is the relatively high 
toxicity of the mycolic acids and the accompanying contaminants during the preparation of 
TDM. A synthetic analog of the cord factor, trehalose-6,6-dibehenate (TDB), was shown to 
be an effective and safe alternative (Davidsen et al., 2005). TDB is less toxic compared with 
TDM and easier to produce, making it a potent candidate in the field of vaccine 
development. 
3. Drug targets in the biosynthesis of the cord factor  
The cord factor (trehalose 6,6´-di-mycolate) is composed of a sugar and a mycolic acid 
component. In the following section we present the trehalose and mycolic acid biosynthesis 
steps and the target enzymes in their biochemical context. Especially enzymes of mycolic 
acid biosynthesis, such as methyl transferase (PcaA) (Glickman et al., 2000), ß-ketoacyl-acyl 
carrier protein synthase (KasAB and FabH) (Bhatt et al., 2007), acyl-AMP ligase (Fad32) 
(Portevin et al., 2005) and polyketide synthase (Psk13) (Portevin et al., 2004), are regarded as 
promising targets for anti-TB drug development.  
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3.1 Biosynthesis of trehalose 
Mycobacteria possess three pathways for trehalose synthesis (Kaur et al., 2009). Trehalose 
can by synthesized from glucose-6-phosphate catalyzed by trehalose-6-phosphate synthase 
(OtsA, Rv3490) (Pan et al., 2002) and trehalose-6-phosphate phosphatase (OtsB2, Rv3372) 
(Pan et al., 2002). The second pathway generates trehalose from glycogen involving the 
maltooligosyltrehalose synthase (TreY, Rv1653c) and the maltooligosyltrehalose 
trehalohydrolase (TreZ, Rv1562c). In the third pathway maltose is converted to trehalose by 
the trehalose synthase (TreS, Rv0126). While all the three pathways are functional and 
essential for the proliferation of M. smegmatis (Woodruff et al., 2004), the OtsAB pathway is 
predominant and strictly essential in M. tuberculosis (Fig. 2). In the genome sequence of M. 
tuberculosis exist two otsB homologues, but only OtsB2 (Rv3372) has a functional role in the 
pathway. OtsB2 has been suggested as an attractive target for novel drugs due to absence of 
trehalose in mammalian cell (Murphy et al., 2005).  
3.2 Trehalose transporters  
The LpqY-SugA-SugB-SugCATP-binding cassette transporter is highly specific for uptake 
of the disaccharide trehalose. Since trehalose is not present in mammals, it is unlikely that 
this system is used for sugar acquisition from the host. Trehalose release is known to 
occur as a byproduct of the biosynthesis of the mycolic acid cell envelope by  
M. tuberculosis antigen 85 complex. The mycolyltransferases of the antigen 85 complex 
transfer the lipid moiety of the glycolipid trehalose monomycolate (TMM) to 
arabinogalactan or another molecule of TMM, yielding trehalose dimycolate. These 
reactions lead to a constant release of trehalose from the cell. The LpqY-SugA-SugB-SugC 
ATP-binding cassette has been suggested as transporter system (Fig. 2), recycling the 
released trehalose. Perturbations in trehalose recycling strongly impaired virulence of  
M. tuberculosis. (Kalscheuer et al., 2010). These sugar transporters are thought to play an 
important role in bacterial pathogenesis and have been suggested as target for 
tuberculosis chemotherapy (Kalscheuer et al., 2010).   
 
Fig. 2. Trehalose biosynthesis in Mycobacterium tuberculosis. 1, OtsAB pathway. 2, TreY-TreZ 
pathway. 3, TreS-pathway. 4, Trehalose import by an ATP-binding cassette transporter 
system.  
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3.3 Mycolic acid biosynthesis     
Mycolic acids are -hydroxy fatty acids with a long -alkyl side chain. They are homologous 
series of fatty acids differing by a two-carbon unit (Asselineau & Lederer, 1950). The mycolic 
acids are composed of an  branch at the alpha position in respect to the carboxylic group 
and a meromycolate branch. The “short”  branch contains species dependent 20-26 
saturated carbon atoms. The “long” meromycolate branch has 50-60 carbon atoms and its 
chemical composition is highly variable, containing cyclopropyl or unsaturated bonds (-
mycolates), methoxy (methoxymycolates) and keto (ketomycolates) groups (Alahari et al., 
2007). The confusing denotation “ǂ-mycolates” refers not to their position in the molecule 
but to their position on thin layer chromatography. The “-mycolates” (cis, cis-
dicyclopropyl fatty acids) are the most abundant mycolic acids in M. tuberculosis (~57%), 
followed by methoxymycolates (32%) and ketomycolates (11%). The methoxy- and 
ketomycolates can have either the cis or trans configuration on the proximal cyclopropane 
ring. In summary there are five main classes of mycolic acids in M. tuberculosis (Schroeder et 
al., 2002; Takayama et al., 2005).  
In M. tuberculosis mycolic acids are essentially provided via conventional fatty acid 
biosynthesis. Mycobacteria contain both type I and type II FAS fatty acid biosynthesis 
systems. Fatty acid biosynthesis is initiated by the multifunctional FAS I enzyme (Rv2524c), 
catalyzing the de novo synthesis of long-chain acyl-CoAs (C16:0 and C18:0) from acetyl-CoA 
and using malonyl-CoA as an extender unit. The domains of the FAS-I multienzyme-
complex are organized in the following order: acyltransferase, enoyl reductase, dehydratase,  
malonyl/palmitoyl transferase, acyl carrier protein (ACP), -keto reductase, -ketoacyl 
synthase (Fernandes & Kolattukudy, 1996). In M. tuberculosis the C16:0- and C18:0-S-ACP 
adducts, are converted either to the CoA derivatives or further elongated by FAS I to 
produce C26:0 (Kikuchi et al., 1992). In mycobacteria the de novo fatty acid biosynthesis is 
exclusively carried out by FAS-I, whereas the FAS-II system performs only the elongation of 
the fatty acids, generated by FAS-I.  The FAS I and FAS II systems are connected by a key 
condensing enzyme, the -ketoacyl ACP synthase III or FabH, which catalyzes a 
decarboxylative condensation of malonyl-ACP with the acyl-CoA (C16:0–C20:0) products of 
the FAS-I system (Fig. 3). The resulting 3-ketoacyl-ACP product is reduced to an acyl-ACP 
(extended by two carbons) and shuffled into the FAS II cycle.  
The ACP cycles the growing acyl chain between four enzymes MabA (ketoacyl 
reductase), -hydroxyacy dehydrase, InhA (enoyl reductase) and KasA/B (-ketoacyl 
synthase).  M. tuberculosis contains two -ketoacyl synthases, KasA and KasB, which share 
67% identity. KasA seems to be essential for growth, while KasB is not essential but 
produces longer carbon chains (Bhatt et al., 2005; Slayden & Barry, 2002; Swanson et al., 
2009). The deletion of KasB in M. tuberculosis leads to mycolic acids that are 2-6 carbons 
shorter in length and a defect in trans-cycloproponation of oxygenated mycolic acids.  
Phenotypically leads a deletion of KasB to a loss of acid-fastness (Bhatt et al., 2007). The most 
potent inhibitor for mycolic acid biosynthesis is isoniazid (INH). INH is a prodrug which is 
converted to the isonicotinoyl radical by KatG. INH forms a covalent adduct with NAD. 
This INH-NAD adduct inhibits FAS-II enoyl-ACP reductase InhA, which in consequence 
leads to inhibition of mycolic acid biosynthesis, and ultimately to cell death (Mdluli et al., 
1998; Takayama et al., 1972; 1975; Wilming & Johnsson, 1999). In M. tuberculosis, the C26:0 
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fatty acids synthesized by FAS I will become the substrate of a dedicated acyl-CoA 
carboxylase (ACCase) to generate the -carboxy C26:0 fatty acid used as one of the substrate 
by the Pks 13 in the biosynthesis of mycolic acids (Gavalda et al., 2009). The last steps of the 
biosynthesis of mycolic acids are catalyzed by proteins encoded by the fadD32-pks13-accD4 
cluster. Pks13 ultimately condenses the two loaded fatty acyl chains to produce -alkyl  
-ketoacids, the precursors of mycolic acids (Gavalda et al., 2009). FadD32 has been shown 
essential for growth (Carroll et al., 2011). Double bonds at specific sites on mycolic acid 
precursors are modified by the action of cyclopropane mycolic acid synthases (CMASs) such 
as MmaA1-A4, PcaA and CmaA2, which are S-adenosyl-methionine-dependent methyl 
transferases (Alahari et al., 2007). The antitubercular drug, thiacetazone (TAC) and its 
chemical analogues acts on CMASs, inhibiting mycolic acid cyclopropanation (Alahari et al., 
2007; Alahari et al., 2009).  
 
Fig. 3. Biosynthesis of mycolic acids for cord factor synthesis. Enzymes are in bold letters. 
Selected inhibitors are depicted in red bold letters. TLM, thiolactomycin. CER, cerulenin. 
ETH, ethionamide. INH, isoniazid. TRC, triclosan. TAC, thiacetazone.  DEP, diethyl 
phosphate. ADT, 6-azido-6-deoxy-ǂ,ǂ′-trehalose (See text for details).   
3.4 TMM biosynthesis  
TDM is thought to be synthesized exclusively outside the cell and its precursor TMM is 
transported outside the cell. In addition TMM has to be exported from the cytoplasm, to 
prevent the degradation of TMM inside the cell by the ubiquitously present Ag85/Fbp 
(Kilburn et al., 1982; Sathyamoorthy & Takayama, 1987). The mycolyl group is first 
transferred from mycolyl-S-Pks13 (mycolyl-S-PPB) to D-mannopyranosyl-1-
phosphoheptaprenol by a proposed cytoplasmic mycolyltransferase I to yield Myc-PL 6-O- 
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mycolyl-ǃ-D-mannopyranosyl -1-phosphoheptaprenol (Myc-PL) (Besra et al., 1994). Myc-PL 
migrates to the inner surface of the cell membrane and docks next to an ABC transporter, 
with its hydrophobic heptaprenol tail. The mycolyl group is transferred to trehalose  
6-phosphate by a proposed membrane-associated mycolyltransferase II to form TMM-
phosphate, and the phosphate group is removed by the membrane-associated trehalose  
6-phosphate phosphatase, yielding TMM. TMM is transported outside the cell by the ABC 
transporter (Fig. 4). There should be virtually no accumulation of TMM in the cytoplasm 
(Takayama et al., 2005). 
 
Fig. 4. The proposed process of incorporation of newly synthesized mycolic acids into major 
cell wall components. The process starts inside the cell. Newly synthesized mycolic acids are 
transferred to man-P-heptaprenol to produce 6-O-mycolyl-ǃ-D-mannopyranosyl-1-
phosphoheptaprenol (Myc-PL) and after that to trehalose 6-phosphate to yield TMM-P by 
the proposed membrane-associated mycolyltransferase II (reaction 1). TMM is produced by 
dephosphorylation of TMM-P by the membrane-bound TMM-P phosphatase (reaction 2). 
The transportation of TMM to the outside is catalyzed by a proposed ABC transporter 
cassette (TMM transporter) (reaction 3). Outside the cell the Ag85 complex catalyzes the 
transfer of mycolate to another TMM and arabinogalactan to yield TDM (reaction 4) or 
arabinogalactan-mycolate (reaction 5) (Takayama et al., 2005).  
3.5 TDM biosynthesis by Ag85 
The antigen 85 complex is composed of Ag85A (FbpA), Ag85B (FbpB), and Ag85C (FbpC) as 
the predominant secreted proteins in M. tuberculosis. The corresponding genes are fbpA 
(Rv3804c), fbpB (Rv1886c), and fbpC (Rv0129c) (Belisle et al., 1997; Wiker & Harboe, 1992). 
The 85 complex proteins share 68–80% sequence identity (Belisle et al., 1997; Ronning et al., 
2004). The mycolyltransferases of the antigen 85 complex are located outside the cell 
membrane and transfer the lipid moiety of the glycolipid trehalose monomycolate (TMM) to 
another molecule of TMM yielding trehalose dimycolate or to arabinogalactan to form cell 
wall arabinogalactan-mycolate (Fig. 4) (Sanki et al., 2009a). 
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There is also evidence, the Ag85 complex proteins bind to fibronectin and the fibronectin-
binding property of the Ag85 complex is important for mycobacterium life cycle in the host 
and macrophages (Klegerman et al., 1994; Ronning et al., 2004). The crystal structures of the 
three 30–32 kDa proteins (Ag85A, B and C) have been determined (Anderson et al., 2001; 
Ronning et al., 2004). These proteins contain a carboxylesterase domain bearing the highly-
conserved consensus sequence GXXSXXG. The interaction between Ag85 and fibronectin is 
mediated by the sequence homologous to residues 56–66 (FEEYYQSGLSV) of the 
recombinant M. tuberculosis Ag85C (Ronning et al., 2004). Up to date, the question remains 
open why Mycobacterium tuberculosis has three antigen 85 enzymes sharing the similar 
sequence and substrate specificity (Daffe, 2000; Ronning et al., 2004).  
Ag85 complex members from M. tuberculosis belong to the ǂ/ǃ hydrolase superfamily and 
catalyze the hydrolysis of ester and amide bonds using a catalytic triad comprised of Ser126, 
Glu230 and His262 in Ag85A/B and Ser124, Glu228 and His260 in Ag85C. All three 
enzymes contain two carbohydrate binding sites. The active site carbohydrate binding 
pocket binds TMM to form a temporary mycolate ester with the catalytic serine. The second 
carbohydrate binding site binds the incoming trehalose monomycolate, which “swings 
over” to the active site to displace the mycolate from its serine ester (Anderson et al., 2001; 
Ronning et al., 2004). The second trehalose binding site is separated from the acyl binding 
pocket by a bulky phenylalanine in Ag85A/B or a smaller leucine in Ag85C. All residues 
that form the active site carbohydrate binding pocket are 100% conserved in the M. 
tuberculosis antigen 85 proteins, while the surface of the acyl binding pocket, which is 
supposed to bind the long mycolate chains of TMM, exhibits slight differences. The 
conserved Leu152 in Ag85A and B is replaced by the bulky Phe150 in Ag85C, which in 
consequence leads to changes of surface topology in the mycolate binding portion (Fig. 5). 
The differences may alter substrate specificity and thus Ag85A, B and C might prefer 
different mycolic acids (Ronning et al., 2000; 2004).  
 
Fig. 5. Surface representation of Ag85A, B and C with two bound trehalose molecules. The 
trehalose molecules are depicted as ball-and-stick model. The position of the catalytic serine 
is indicated by a yellow asterisk. The carbohydrate binding pocket of all three proteins is 
100% conserved (Arg43, Gln45 Ile53, Asn54, Trp264 in Ag85A and B) and Arg41, Gln43, 
Ile51, Asn52, Trp264 in Ag85C. Corresponding residues, which differ among the three 
proteins are shown with red labels. The separation of the second carbohydrate binding 
pocket from the acyl binding pocket by the Phe232 in Ag85A/B and the corresponding 
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smaller Leu230 in Ag85C is highlighted by an arrow. Also shown: Arginine 233, which 
covers the second carbohydrate binding pocket in Ag85C is replaced by smaller polar amino 
acids Thr235 and Ser235 in Ag85A and B, respectively. The surface is colored by electrostatic 
potential: The red and blue coloring represent negative and positive electrostatic potential, 
respectively. For Ag85A, B and C the coordinates from 1SFR, 1F0P and 1DQZ were used, 
respectively. The position of the trehalose molecules in Ag85A and Ag85C were modeled 
using the coordinates from 1F0P. The figure was prepared using GRASP (Nicholls et al., 
1991). 
3.6 Ag85 as a putative drug target for tuberculosis treatment 
The ongoing treatment battle of tuberculosis is worsened by the emergence of new strains of 
M. tuberculosis which are resistant to standard antibiotics.  In the urgent need of new targets 
the biogenesis of fatty acids, mycolic acids and glycolipids stay as hotspots. There is hope 
that the crystal structure of antigen 85A, 85B and 85C shall help in rational drug 
development for TB (Ronning et al., 2000; 2004).  
The treatment by a trehalose analogue, 6-azido-6-deoxy-ǂ,ǂ′-trehalose (ADT) inhibited the 
activity of all members of Ag85 complex in vitro and the growth of Mycobacterium aurum, 
and it also increased the efficacy of various antibiotics, supporting the importance of TDM 
(Belisle et al., 1997; Mizuguchi et al., 1983). M. tuberculosis strain lacking Ag85C has a 40% 
decrease in the amount of cell wall linked mycolic acid, but with no change in the relative  
amounts of TMM and TDM (Jackson et al., 1999; Sanki et al., 2009a). Furthermore, an Ag85A 
knockout strain lost the ability to grow in macrophage-like cell-lines and poor media which 
highlights the role of Ag85A in virulence and survival of the organism (Armitige et al., 
2000). In the last decades several antitubercular drugs have focused on targets in the 
mycobacterial cell wall (Johnson et al., 2006). Most commonly, ethambutol targets the 
synthesis of arabinogalactan. Isoniazid and ethionamide inhibit biosynthesis of mycolic 
acids (Johnson et al., 2006). Obviously, the crystal structure of antigen 85 complex is 
expected to accelerate the design of new drugs against Ag85 activity and cord factor 
biosynthesis (Table 1) (Gobec et al., 2004; Sanki et al., 2009b; Wang et al., 2004).  
4. Drug development: Novel high-throughput screening assays for 
mycolytransferase 85A 
Since the protein/substrate interactions and co-crystal structure of Ag85 are now known, 
the search for rapid assays for high-throughput screening (HTS) of large substance libraries 
has increased considerably. Most of the mycolyltransferase assays previously published are 
not suitable for HTS, due to their complexity or use of radioactive substances. The first one 
is a widely used radioassay which monitors enzymatic transfer of mycolic acids from a 
lipid-soluble TMM molecule to a radioactive water-soluble trehalose. Manipulation of the 
radioactive products in a two-phase reaction, extraction and thin layer chromatography 
allows visualization of the products (Kremer et al., 2002; Sathyamoorthy & Takayama, 1987). 
Another test published uses the substrate analogue p-nitrophenyl-6-O-octanoyl-H-D-
glucopyranoside that functions as the acyl donor but it may not represent the natural 
enzymatic activity (Boucau et al., 2009). Also an excess of D-glucose is added to the reaction 
to function as an acyl acceptor and to promote turnover of the enzyme. Recently new assay 
www.intechopen.com
 
Understanding Tuberculosis – New Approaches to Fighting Against Drug Resistance 
 
196 
for Ag85 was developed based on the use of mono and dihexanoyl trehalose substrates, 
followed by quantitation of the acyl-transfer to the unnatural trehalose by mass 
spectrometry (Backus et al., 2011). 
Synthesis step Enzyme Compound / class References 
FAS-I and 
FAS-II  
KasA/KasB Cerulenin (2R,3S-epoxy-4-oxo-
7,10-trans,trans-dodecanoic 
acid amide 
(Schroeder et al., 
2002) (Johansson et 
al., 2008) 
FAS-II KasA/KasB TLM (Thiolactomycin) (Douglas et al., 2002; 
Kremer et al., 2000; 
Luckner et al., 2010) 
FAS-II KasA/KasB Platensimycin (Brown et al., 2009) 
 InhA INH (Isoniazid) (Slayden et al., 2000) 
 InhA ETH (Ethionamide) (Kremer et al., 2003) 
 InhA TRC (Triclosan) (McMurry et al., 
1999) 
 InhA alkyl diphenyl ethers (Triclosan 
derivatives) 
(Sullivan et al., 2006) 
 InhA 2-(o-Tolyloxy)-5-hexylphenol 
(PT70) 
(Luckner et al., 2010) 
Mycolic acid 
biosynthesis 
Unknown   N-octanesulfonylacetamide (Parrish et al., 2001) 
Cyclopro-
panation  
CMASs (cmaA2, 
mmaA2 or pcaA) 
TAC (Thiacetazone) (Alahari et al., 2007) 
 MmaA4 TAC (Thiacetazone) (Alahari et al., 2007) 
Cord-factor 
biosynthesis  
Ag85C Methyl ǃ-D-arabinofuranoside (Sanki et al., 2009b) 
 Ag85C 5-S-alkyl-5-thio-
arabinofuranoside analogues 
(Sanki et al., 2008) 
 Ag85 complex  Trehalose analogues (Wang et al., 2004) 
 Ag85 complex ADT  (6-azido-6-deoxy-ǂ,ǂ′-
trehalose) 
(Belisle et al., 1997; 
Mizuguchi et al., 
1983) 
 Ag85 complex  Phosphonate compounds (Gobec et al., 2004; 
Gobec et al., 2007) 
 Ag85C DEP (Diethyl phosphate)  (Ronning et al., 2000) 
Table 1. Inhibitors of cord factor biosynthesis  
The mycobacterial glycolipids and TMM levels in the cell wall might give an indirect 
indication of the fitness of the cell inside the host cells specially in macrophages. Thus the 
quantitation of the mycobacterial TMM status after drug treatment may allow the 
estimation of drug effectiveness. Unfortunately, there is no method for measurement of 
the amount of glycolipids that is suitable for HTS. We designed an assay (Elamin et al., 
2009) based on the use of natural substrate, and this mycolyltransferase assay offers a 
novel means to determine the TMM status of the  mycobacterium cell wall and reflects the 
natural activity of mycolyltransferase enzyme based on simple steps. The new assay uses 
the natural substrate TMM, which can be easily purified from mycobacteria (Fujita et al., 
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2005) and reflects natural activity, allowing to get the most accurate kinetic parameters.  
In the reaction Ag85A produces one molecule of trehalose as product per reaction cycle 
and by adding trehalase the trehalose converted to glucose, which can be easily measured 
(Fig. 6).  
 
Fig. 6. Scheme for the new mycolyltransferase activity assay. Using trehalose that is 
produced as one of final products of mycolyltransferase reaction by trehalase to produce 
glucose, which is oxidized to gluconic acid and hydrogen peroxidase by glucose oxidase. 
Hydrogen peroxide reacts with o-dianisidine in the presence of peroxidase to produce a 
colored product (oxidized o-dianisidine), which will be converted to a stable colored 
product by sulfuric acid. The colored product is measured at 540 nm  
(Elamin et al., 2009). 
Quantification of glucose is finally achieved by the glucose oxidase assay (Washko & Rice, 
1961). The amount of glucose is proportional to the TMM concentration. The assay showed 
that the antigen 85A can be assayed in the presence of methanol or mixture of 
chloroform/methanol, which is usually used to extract and purify the glycolipids from 
mycobacterium cell wall fractions. The results from substrate/solvent experiments showed 
that the enzyme activity was reduced in the presence of organic solvents than in standard 
buffer reaction alone. This indicates and proves that this method is useful to quantify the 
TMM from the total lipid of mycobacterium cells. 
One molecule of trehalose produced from TMM processed by Ag85 complex, which by our 
method is converted to two molecules of glucose. We can calculate the original 
concentration of TMM and concentration of TDM and trehalose in the reaction by the 
following equations: 
 Concentration of [TMM] = concentration of [glucose] (1) 
 Concentration of [TDM] = concentration of [glucose]/2 (2) 
 Concentration of [trehalose] = concentration of [glucose]/2 (3) 
One has to keep in mind that the extracted total lipids contain free trehalose and glucose 
and will affect the final calculations.  In this case and to calculate the TMM concentration in 
total lipids one should run different negative controls. The Z′ factor (Zhang et al., 1999) 
measurement of the current assay in different volumes indicates an excellent signal/noise 
(S/N) ratio for the assay and its high potential for HTS applications (Table 2).   
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Reaction volume 200 µl 300 µl 350 µl 
Z′ factor 0.67 ±0.021 0.72 ± 0.014 0.73 ±0.012
Table 2. The calculated Z′ factor at different volumes from 96-well plate format assays.  
5. Concluding remarks 
Large gaps remain in our understanding of mycobacterium pathogenesis and persistence 
including the critical questions how bacteria survive in host cells and escape from the 
therapy. Future work on mycobacterial cell wall biosynthesis especially glycolipids and 
related pathways is expected to reveal in vivo drug-resistance mechanism. Perhaps more 
notably, the described new and low-cost colorimetric method based on use of TMM as 
natural substrate could brings flexibility and convenience in HT-screening of substance 
libraries and help in the development of novel drugs against tuberculosis. 
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